RBC Capital analyst Brian Abrahams maintained a Hold rating on Enanta Pharmaceuticals (ENTA – Research Report) on July 7 and set a price target of $67.00. The company’s shares closed last Friday at $52.76.
According to TipRanks.com, Abrahams is a 1-star analyst with an average return of -1.0% and a 46.5% success rate. Abrahams covers the Healthcare sector, focusing on stocks such as Intra-Cellular Therapies, Karyopharm Therapeutics, and Vertex Pharmaceuticals.
Currently, the analyst consensus on Enanta Pharmaceuticals is a Moderate Buy with an average price target of $67.75.
The company has a one-year high of $102.00 and a one-year low of $37.59. Currently, Enanta Pharmaceuticals has an average volume of 292.5K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ENTA in relation to earlier this year. Last month, Paul Mellett, the Treas. & CFO of ENTA bought 3,480 shares for a total of $40,960.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Enanta Pharmaceuticals, Inc. operates as a biotechnology company. It engages in the research and development of molecule drugs for the treatment of viral infections and liver diseases. The firm offers the medicine under the brands Mavyret and Viekira Pak. The company was founded by Peter O. Kliem and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.
Read More on ENTA: